Rifampin (INN Rifampicin)

Paul Howard, Robert Twycross, Graham Grove, Sarah Charlesworth, Mary Mihalyo, Andrew Wilcock

Research output: Contribution to journalArticle

Abstract

[Extract] The bactericidal activity of rifampin is due to inhibition of bacterial RNA polymerase. Rifampin is also a pregnane X receptor (PXR) agonist, one of several receptors involved in upregulating enzymes and transporters required for the removal of xenobiotics, e.g., drugs, and endogenous metabolites, e.g., bile acids.

Pooled RCT data (n=61) support the efficacy of rifampin in cholestatic pruritus with an NNT of 1.75. Participants had various non-cancer causes of cholestasis, mostly (80%) primary biliary cirrhosis (PBC). The RCTs were short-term (≤2 weeks), but longer-term benefit (≤2 years) has been reported.
LanguageEnglish
Pages891-895
Number of pages5
JournalJournal of Pain and Symptom Management
Volume50
Issue number6
DOIs
Publication statusPublished - Dec 2015
Externally publishedYes

Fingerprint

Rifampin
Bacterial RNA
Biliary Liver Cirrhosis
Cholestasis
Xenobiotics
DNA-Directed RNA Polymerases
Pruritus
Bile Acids and Salts
Enzymes
Pharmaceutical Preparations

Cite this

Howard, P., Twycross, R., Grove, G., Charlesworth, S., Mihalyo, M., & Wilcock, A. (2015). Rifampin (INN Rifampicin). Journal of Pain and Symptom Management, 50(6), 891-895. https://doi.org/10.1016/j.jpainsymman.2015.09.004
Howard, Paul ; Twycross, Robert ; Grove, Graham ; Charlesworth, Sarah ; Mihalyo, Mary ; Wilcock, Andrew. / Rifampin (INN Rifampicin). In: Journal of Pain and Symptom Management. 2015 ; Vol. 50, No. 6. pp. 891-895.
@article{f9ab34f12bfb437ea2851fbf44438bae,
title = "Rifampin (INN Rifampicin)",
abstract = "[Extract] The bactericidal activity of rifampin is due to inhibition of bacterial RNA polymerase. Rifampin is also a pregnane X receptor (PXR) agonist, one of several receptors involved in upregulating enzymes and transporters required for the removal of xenobiotics, e.g., drugs, and endogenous metabolites, e.g., bile acids.Pooled RCT data (n=61) support the efficacy of rifampin in cholestatic pruritus with an NNT of 1.75. Participants had various non-cancer causes of cholestasis, mostly (80{\%}) primary biliary cirrhosis (PBC). The RCTs were short-term (≤2 weeks), but longer-term benefit (≤2 years) has been reported.",
author = "Paul Howard and Robert Twycross and Graham Grove and Sarah Charlesworth and Mary Mihalyo and Andrew Wilcock",
year = "2015",
month = "12",
doi = "10.1016/j.jpainsymman.2015.09.004",
language = "English",
volume = "50",
pages = "891--895",
journal = "Journal of Pain and Symptom Management",
number = "6",

}

Howard, P, Twycross, R, Grove, G, Charlesworth, S, Mihalyo, M & Wilcock, A 2015, 'Rifampin (INN Rifampicin)' Journal of Pain and Symptom Management, vol. 50, no. 6, pp. 891-895. https://doi.org/10.1016/j.jpainsymman.2015.09.004

Rifampin (INN Rifampicin). / Howard, Paul; Twycross, Robert; Grove, Graham; Charlesworth, Sarah; Mihalyo, Mary; Wilcock, Andrew.

In: Journal of Pain and Symptom Management, Vol. 50, No. 6, 12.2015, p. 891-895.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rifampin (INN Rifampicin)

AU - Howard, Paul

AU - Twycross, Robert

AU - Grove, Graham

AU - Charlesworth, Sarah

AU - Mihalyo, Mary

AU - Wilcock, Andrew

PY - 2015/12

Y1 - 2015/12

N2 - [Extract] The bactericidal activity of rifampin is due to inhibition of bacterial RNA polymerase. Rifampin is also a pregnane X receptor (PXR) agonist, one of several receptors involved in upregulating enzymes and transporters required for the removal of xenobiotics, e.g., drugs, and endogenous metabolites, e.g., bile acids.Pooled RCT data (n=61) support the efficacy of rifampin in cholestatic pruritus with an NNT of 1.75. Participants had various non-cancer causes of cholestasis, mostly (80%) primary biliary cirrhosis (PBC). The RCTs were short-term (≤2 weeks), but longer-term benefit (≤2 years) has been reported.

AB - [Extract] The bactericidal activity of rifampin is due to inhibition of bacterial RNA polymerase. Rifampin is also a pregnane X receptor (PXR) agonist, one of several receptors involved in upregulating enzymes and transporters required for the removal of xenobiotics, e.g., drugs, and endogenous metabolites, e.g., bile acids.Pooled RCT data (n=61) support the efficacy of rifampin in cholestatic pruritus with an NNT of 1.75. Participants had various non-cancer causes of cholestasis, mostly (80%) primary biliary cirrhosis (PBC). The RCTs were short-term (≤2 weeks), but longer-term benefit (≤2 years) has been reported.

U2 - 10.1016/j.jpainsymman.2015.09.004

DO - 10.1016/j.jpainsymman.2015.09.004

M3 - Article

VL - 50

SP - 891

EP - 895

JO - Journal of Pain and Symptom Management

T2 - Journal of Pain and Symptom Management

JF - Journal of Pain and Symptom Management

IS - 6

ER -

Howard P, Twycross R, Grove G, Charlesworth S, Mihalyo M, Wilcock A. Rifampin (INN Rifampicin). Journal of Pain and Symptom Management. 2015 Dec;50(6):891-895. https://doi.org/10.1016/j.jpainsymman.2015.09.004